Leaderna Therapeutics key facts
as of Oct 2026- Developer of nucleic acid-based therapeutic research designed to advance targeted biological interventions.
- Leaderna Therapeutics is valued at approximately $33.9M as of Oct 2026 (last reported valuation).
- It has raised $44.9M; the latest was Early Stage VC ($21.8M) in Mar 2026.
- Notable investors include CAS Star, CDH Investments, Sky9 Capital, Chengdu Venture Capital Group, Tianjin Venture Capital — 14 tracked in total.
- Status: Privately Held (backing).
Leaderna Therapeutics's last reported valuation, Dec 2022. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Leaderna Therapeutics: the Monday email on marks, rounds and moves
Leaderna Therapeutics funding rounds
No funding rounds for Leaderna Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Leaderna Therapeutics
14+Leaderna Therapeutics valuation
Leaderna Therapeutics's last reported valuation was $33.9 million in Dec 2022. No priced round, secondary trade or fund mark has surfaced since.
Leaderna Therapeutics investors
14 investors are on record for Leaderna Therapeutics, including CAS Star, CDH Investments, Sky9 Capital and Chengdu Venture Capital Group.
About Leaderna Therapeutics
Developer of nucleic acid-based therapeutic research designed to advance targeted biological interventions. The company offers project development in nucleic acid modalities, platform-driven investigation of drug candidates, and technical expertise spanning design, modification, and evaluation of oligonucleotide constructs, enabling researchers and biotechnology organizations to pursue precise therapeutic targets and enhance experimental reliability.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2022
- Employees
- 16
- Website
- leadernatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.